Literature DB >> 22402866

Autoantibodies and high-risk HLA susceptibility markers in first-degree relatives of Brazilian patients with type 1 diabetes mellitus: a progression to disease based study.

L I Alves1, E Davini, M R Correia, R T Fukui, R F Santos, M R Cunha, D M Rocha, W M G Volpini, M E R Silva.   

Abstract

PURPOSE: The objective of this study was to determine the frequencies of autoantibodies to heterogeneous islet-cell cytoplasmic antigens (ICA), glutamic acid decarboxylase(65) (GAD(65)A), insulinoma-associated antigen-2 (IA-2A) and insulin (IAA)-and human leukocyte antigen (HLA) class II markers (HLA-DR and -DQ) in first degree relatives of heterogeneous Brazilian patients with type I diabetes (T1DM). A major focus of this study was to determine the influence of age, gender, proband characteristics and ancestry on the prevalence of autoantibodies and HLA-DR and -DQ alleles on disease progression and genetic predisposition to T1DM among the first-degree relatives.
METHODS: IAA, ICA, GAD(65)A, IA-2A and HLA- class II alleles were determined in 546 first-degree-relatives, 244 siblings, 55 offspring and 233 parents of 178 Brazilian patients with T1DM.
RESULTS: Overall, 8.9% of the relatives were positive for one or more autoantibodies. IAA was the only antibody detected in parents. GAD(65) was the most prevalent antibody in offspring and siblings as compared to parents and it was the sole antibody detected in offspring. Five siblings were positive for the IA-2 antibody. A significant number (62.1%) of siblings had 1 or 2 high risk HLA haplotypes. During a 4-year follow-up study, 5 siblings (expressing HLA-DR3 or -DR4 alleles) and 1 offspring positive for GAD(65)A progressed to diabetes.
CONCLUSIONS: The data indicated that the GAD(65) and IA-2 antibodies were the strongest predictors of T1DM in our study population. The high risk HLA haplotypes alone were not predictive of progression to overt diabetes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22402866     DOI: 10.1007/s10875-012-9673-4

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  48 in total

1.  Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study.

Authors:  C J Greenbaum; K L Sears; S E Kahn; J P Palmer
Journal:  Diabetes       Date:  1999-01       Impact factor: 9.461

Review 2.  [Distribution and frequency of HLA alleles and haplotypes in Brazilians with type 1 diabetes mellitus].

Authors:  Crésio Alves; Isadora Meyer; Nara Vieira; Maria Betânia P Toralles; Denise LeMaire
Journal:  Arq Bras Endocrinol Metabol       Date:  2006-06

3.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

4.  Pancreatic islet cell and thyroid antibodies, and islet cell function in diabetic patients of Mexican-American origin.

Authors:  A Zeidler; S D Frasier; R Penny; R B Stein; J T Nicoloff
Journal:  J Clin Endocrinol Metab       Date:  1982-05       Impact factor: 5.958

Review 5.  Type 1 diabetes: pathogenesis and prevention.

Authors:  Kathleen M Gillespie
Journal:  CMAJ       Date:  2006-07-18       Impact factor: 8.262

6.  Incidence of type 1 diabetes mellitus in Passo Fundo, RS, Brazil.

Authors:  H R Lisbôa; R Graebin; L Butzke; C S Rodrigues
Journal:  Braz J Med Biol Res       Date:  1998-12       Impact factor: 2.590

7.  Islet autoantibodies are associated with HLA-DQ genotypes in Han Chinese patients with type 1 diabetes and their relatives.

Authors:  J-P Wang; Z-G Zhou; J Lin; G Huang; C Zhang; L Yang; Y Yuan; H-F Zhou; M Zhou; C Hou; W-D Zhou; H Peng; W A Hagopian
Journal:  Tissue Antigens       Date:  2007-11

Review 8.  HLA and insulin-dependent diabetes. A protective perspective.

Authors:  M J Sheehy
Journal:  Diabetes       Date:  1992-02       Impact factor: 9.461

9.  Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes.

Authors:  Maria J Redondo; Sunanda Babu; Adina Zeidler; Tihamer Orban; Liping Yu; Carla Greenbaum; Jerry P Palmer; David Cuthbertson; George S Eisenbarth; Jeffrey P Krischer; Desmond Schatz
Journal:  J Clin Endocrinol Metab       Date:  2006-02-07       Impact factor: 5.958

10.  Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes.

Authors:  E Bonifacio; P J Bingley; M Shattock; B M Dean; D Dunger; E A Gale; G F Bottazzo
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

View more
  3 in total

1.  Screening of endocrine organ-specific humoral autoimmunity in 47,XXY Klinefelter's syndrome reveals a significant increase in diabetes-specific immunoreactivity in comparison with healthy control men.

Authors:  Francesca Panimolle; Claudio Tiberti; Simona Granato; Antonella Semeraro; Daniele Gianfrilli; Antonella Anzuini; Andrea Lenzi; Antonio Radicioni
Journal:  Endocrine       Date:  2015-05-03       Impact factor: 3.633

2.  Enterovirus Neutralizing Antibodies, Monocyte Toll Like Receptors Expression and Interleukin Profiles Are Similar Between Non-affected and Affected Siblings From Long-Term Discordant Type 1 Diabetes Multiplex-Sib Families: The Importance of HLA Background.

Authors:  Carla Sanchez Bergamin; Elizabeth Pérez-Hurtado; Luanda Oliveira; Monica Gabbay; Valdecira Piveta; Célia Bittencourt; Denise Russo; Rita de Cássia Carmona; Maria Sato; Sergio A Dib
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-23       Impact factor: 5.555

3.  CD226 rs763361 is associated with the susceptibility to type 1 diabetes and greater frequency of GAD65 autoantibody in a Brazilian cohort.

Authors:  Teresa Cristina Colvara Mattana; Aritania Sousa Santos; Rosa Tsuneshiro Fukui; Debora Teixeira Oliveira Mainardi-Novo; Vinícius Silva Costa; Rosa Ferreira Santos; Sergio Russo Matioli; Maria Elizabeth Rossi da Silva
Journal:  Mediators Inflamm       Date:  2014-05-07       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.